Lung Cancer (Auckland, N.Z.)

Keyphrases

Publications

volume 15, 2024

Zhaohui Liao Arter, Misako Nagasaka
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)
Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Lung Cancer (Auckland, N.Z.) 15 (2024)
Baofeng Wang, Jiang Wang, Tongyu Sun, Yilin Ding, Shasha Li, Hengxiao Lu
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach. Lung Cancer (Auckland, N.Z.) 15 (2024)
Faustine X Luo, Sai-Hong Ignatius Ou
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834). Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Maria González-Cao, Xueting Cai, Jillian Wilhelmina Paulina Bracht, Xuan Han, Yang Yang, Carlos Pedraz-Valdunciel, Teresa Morán, Javier García-Corbacho, Andrés Aguilar, Reyes Bernabé, Pedro De Marchi, Luciane Sussuchi da Silva, Leticia Ferro Leal, Rui Manuel Vieira Reis, Jordi Codony-Servat, Eloísa Jantus-Lewintre, Miguel Angel Molina-Vila, Peng Cao, Rafael Rosell
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 15 (2024)
Xue-Jun Dou, Run-Yang Ma, De-Wang Ren, Qiang Liu, Peng Yan
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Maria González-Cao, Xueting Cai, Jillian Wilhelmina Paulina Bracht, Xuan Han, Yang Yang, Carlos Pedraz-Valdunciel, Teresa Morán, Javier García-Corbacho, Andrés Aguilar, Reyes Bernabé, Pedro De Marchi, Luciane Sussuchi da Silva, Leticia Ferro Leal, Rui Manuel Vieira Reis, Jordi Codony-Servat, Eloísa Jantus-Lewintre, Miguel Angel Molina-Vila, Peng Cao, Rafael Rosell
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 15 (2024)
Baofeng Wang, Jiang Wang, Tongyu Sun, Yilin Ding, Shasha Li, Hengxiao Lu
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach. Lung Cancer (Auckland, N.Z.) 15 (2024)
Faustine X Luo, Sai-Hong Ignatius Ou
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834). Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Misako Nagasaka
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckland, N.Z.) 15 (2024)
Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation. Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Xue-Jun Dou, Run-Yang Ma, De-Wang Ren, Qiang Liu, Peng Yan
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study. Lung Cancer (Auckland, N.Z.) 15 (2024)
Dalia Kaakour, Misako Nagasaka
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions. Lung Cancer (Auckland, N.Z.) 15 (2024)
Qian Liu, Jun Zhang, Mingqin Wei, Xue Zhou, Hao Sun, Youhong Dong, Dongdong Zhang
Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature. Lung Cancer (Auckland, N.Z.) 15 (2024)
Zhaohui Liao Arter, Misako Nagasaka
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK -Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Jinlian Zhu, Jie Chen, Wei Liu, Junling Zhang, Yulan Gu
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)

volume 14, 2023

Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Jared Deck, Marissa Hartley, Mohammad Akhter, Dongliang Wang, Jeffrey A Bogart, Michael D Mix
Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 14 (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Jennifer Kim, Sai-Hong Ignatius Ou
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C + NSCLC Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Jennifer Kim, Sai-Hong Ignatius Ou
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C + NSCLC Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Jinpeng Shi, Jiayu Li, Haowei Wang, Xuefei Li, Qi Wang, Chao Zhao, Lei Cheng, Ruoshuang Han, Peixin Chen, Haoyue Guo, Zhuoran Tang, Caicun Zhou, Zhemin Zhang, Fengying Wu
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer. Lung Cancer (Auckland, N.Z.) 14 (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia. Lung Cancer (Auckland, N.Z.) 14 (2023)
Maria Concetta Nigro, Paola Valeria Marchese, Chiara Deiana, Chiara Casadio, Linda Galvani, Alessandro Di Federico, Andrea De Giglio
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Li Wang, Fei Quan, Zhen Guo, Zhongyu Lu, Duoxia Yang, Meiqi Shi
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib. Lung Cancer (Auckland, N.Z.) 14 (2023)